Source: Lieyun Network
Recently, Horimed Technology Co., Ltd. (hereinafter referred to as "Horimed") announced the completion of a financing round exceeding 100 million yuan. This round of financing was led by CICC Capital and Xichuang Investment, with additional investment from Chengdu Science and Technology Investment, an existing shareholder. This is an important financing completed by Horimed in early 2026, which will help the company further accelerate the research and development, production, and commercialization process of intravascular interventional imaging and treatment-related products.
Tianyancha shows that Horimed, established in 2016, focuses on the independent research, production, and sales of Intravascular Ultrasound (IVUS) equipment and catheters, Optical Coherence Tomography (OCT) equipment and catheters, dual-catheter systems integrated with IVUS/OCT, and intravascular laser plaque ablation technology.
The company owns technology platforms in optics, ultrasound, artificial intelligence, and endoscopic catheters, and is committed to providing an integrated pan-vascular solution based on imaging products for doctors and patients.
Based on in-depth market analysis and technical evaluation, Horimed has expanded its layout to include cerebral vascular OCT, carotid artery OCT, peripheral vascular IVUS, and an OCT+IVUS+NIRS multimodal imaging system. In terms of cardiac ultrasound systems, the 2D ICE system has entered the registration phase; the 4D ICE (industry-leading ASIC+PZT electronic matrix mode) is set to enter the registration phase by the end of 2026; the ICE+TTE+TEE integrated cardiac ultrasound system will also enter the registration phase in 2026.
A relevant person in charge of CICC Capital stated: "This investment in Horimed is a key step for CICC Capital’s strategic layout in China’s vascular intervention field. We highly value the company's independent innovation in products such as IVUS and OCT, which have broken overseas monopolies. As a leading enterprise in China’s vascular interventional endovascular imaging field, Horimed has deeply cultivated the precision diagnosis and treatment track for泛vascular diseases. With independent innovation as its core driving force, the company has built a full-chain technology barrier from core components to complete systems, becoming a crucial force in promoting the import substitution and clinical popularization of domestically produced high-end medical devices."